ClinicalTrials.Veeva
Menu

Find clinical trials for Kidney Disease in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Kidney Diseases
Chronic Renal Insufficiency
Chronic Kidney Failure
IGA Glomerulonephritis
Renal Cell Carcinoma
Renal Insufficiency
Carcinoma

Kidney Disease trials near New York, NY, USA:

A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

This is a Phase 3 Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hem...

Enrolling
Chronic Kidney Disease
Secondary Hyperparathyroidism
Drug: Etelcalcetide

Phase 3

Amgen
Amgen

New York, New York, United States and 42 other locations

This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and...

Enrolling
Chronic Kidney Disease
Drug: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD
Drug: Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD

Phase 2

Mineralys Therapeutics

Brooklyn, New York, United States and 43 other locations

Primary Objectives:To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemi...

Enrolling
Chronic Kidney Disease; Iron Deficiency Anemia
Drug: Iron sucrose
Drug: Ferumoxytol

Phase 3

AMAG Pharmaceuticals
AMAG Pharmaceuticals

New York, New York, United States and 20 other locations

A) or REGN5458 (Part B) as monotherapy in patients with chronic kidney disease (CKD) who need kidney transplantation and a...

Enrolling
Chronic Kidney Disease (CKD)
Drug: REGN5458
Drug: REGN5459

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

New York, New York, United States and 8 other locations

to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney...

Enrolling
Chronic Kidney Disease With High Proteinuria
Drug: Dapagliflozin
Drug: Zibotentan/Dapagliflozin

Phase 3

AstraZeneca
AstraZeneca

Smithtown, New York, United States and 338 other locations

Primary Objective:Evaluate the effect of Hectorol® capsules in reducing elevated levels of intact parathyroid hormone (iPTH).Secondary Objectives:* E...

Active, not recruiting
Secondary Hyperparathyroidism-Chronic Kidney Disease
Drug: Doxercalciferol (GZ427397)
Drug: Calcitriol

Phase 3

Sanofi
Sanofi

New York, New York, United States and 29 other locations

tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney...

Enrolling
Proteinuric Kidney Disease
Drug: Placebo
Drug: VX-147

Phase 2, Phase 3

Vertex Pharmaceuticals
Vertex Pharmaceuticals

New York, New York, United States and 279 other locations

This study will look if CagriSema can lower kidney damage in people with chronic kidney disease (CKD), type 2 diabetes (T2...

Enrolling
Chronic Kidney Disease
Obesity
Drug: Placebo
Drug: Cagrilintide

Phase 2

Novo Nordisk
Novo Nordisk

New York, New York, United States and 114 other locations

Locations recently updated

The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the cl...

Enrolling
Chronic Kidney Disease
Cardiac Disease
Drug: Placebo
Drug: Ravulizumab

Phase 3

Alexion Pharmaceuticals
Alexion Pharmaceuticals

Valhalla, New York, United States and 186 other locations

This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double blind, placebo controlled study. Part 1 (phase 2b) is a do...

Enrolling
Atherosclerotic Cardiovascular Disease
End Stage Kidney Disease
Drug: CSL300
Drug: Placebo

Phase 2, Phase 3

CSL Behring
CSL Behring

College Point, New York, United States and 93 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems